pancreatic ductal adenocarcinoma

[Journal of Experimental & Clinical Cancer Research] Scientists investigated the potential of domatinostat, a new class I histone deacetylase inhibitor, currently in clinical development, to sensitize PDAC to first line standard gemcitabine/taxol doublet chemotherapy treatment.

[Scientific Reports] Researchers utilized high resolution flow cytometry to detect EVs in the plasma of patients with pancreatic ductal adenocarcinoma (PDAC) and in the supernatants of PDAC and healthy control pancreatic organoid cultures.

[Aging] Scientists characterized a novel pseudogene-miRNA-mRNA network associated with PDAC progression using bioinformatics analysis. After screening by dreamBase and GEPIA, 12 up-regulated and 7 down-regulated differentially expressed pseudogenes were identified.

[Cell Death & Disease] The authors studied the specific function of Numb-PRRL isoform in activated EMT of pancreatic ductal adenocarcinoma, which was distinguished from our previous studies that only focused on the total Numb protein.

[Proceedings of the National Academy of Sciences of the United States of America] In NOXA-deficient isogenic cellular models, the authors identified an inhibitor of the transcription factor heterodimer CBFβ/RUNX1.

[Proceedings of the National Academy of Sciences of the United States of America] By genetic gain and loss of function experiments, scientists validated that mode of action dependWS on RUNX1 and NOXA.